X-ALD, from Lorenzo's oil to gene therapy

In 1992, the film Lorenzo's Oil dramatized the story of Augusto and Michaela Odone, parents who responded to their son's diagnosis of X-linked adrenoleukodystrophy by working with biochemists to formulate a dietary intervention from oleic and erucic acids. The film made X-ALD culturally visible. It also embedded a generation's understanding of the disease around an intervention whose actual benefit, when subjected to long-term randomized study, turned out to be modest at best for the cerebral form and absent for adrenal involvement.

In 2022, the FDA approved elivaldogene autotemcel, marketed as Skysona, for cerebral X-ALD in boys aged 4 to 17. Skysona is an autologous CD34-positive cell therapy transduced with a lentiviral vector encoding functional ABCD1, the gene whose loss-of-function variants cause X-ALD. The thirty years between Lorenzo's Oil and Skysona is a useful index of how rare disease therapy actually moves: cultural attention came early, real disease modification came late, and the work in between was largely invisible.

What X-ALD is

X-linked adrenoleukodystrophy is an X-linked peroxisomal disorder caused by variants in ABCD1 on Xq28. ABCD1 encodes the adrenoleukodystrophy protein, an ATP-binding cassette transporter that imports very long-chain fatty acids, VLCFAs, into the peroxisome for beta-oxidation. Without functional ABCD1, VLCFAs accumulate in plasma, in the brain, in the spinal cord, in the testes, and in the adrenal cortex. The clinical consequences cluster around three phenotypes: cerebral demyelination, slowly progressive myelopathy (adrenomyeloneuropathy), and primary adrenal insufficiency. The same ABCD1 variant within a family can produce different phenotypes in different relatives. Genotype-phenotype correlation is poor.

The cerebral form, sometimes called childhood cerebral ALD, presents typically between ages 4 and 12 in affected boys with attentional, behavioral, or learning regression that progresses over months to severe neurological disability. The MRI findings are characteristic: a contrast-enhancing demyelinating lesion that begins in the splenium of the corpus callosum and spreads outward. Without intervention, the cerebral form progresses to a vegetative state and death within a few years. Roughly 30 to 40 percent of boys with X-ALD develop the cerebral form. The remainder develop adrenal insufficiency, adrenomyeloneuropathy in adulthood, or isolated biochemical abnormality.

Adrenomyeloneuropathy, AMN, is the adult form. It presents in the third or fourth decade with progressive spastic paraparesis, sensory abnormalities, and bowel and bladder dysfunction. Female heterozygotes can develop a milder AMN-like syndrome in adulthood, particularly in the fifth decade and beyond.

Primary adrenal insufficiency develops in the majority of affected males by adulthood and can present as the first manifestation, sometimes in childhood, before any neurological involvement. Adrenal crisis is the historical lethal event in unscreened, unmonitored X-ALD.

Reported X-ALD prevalence in unscreened populations runs roughly 1 in 14,000 to 1 in 17,000 male births. The condition is panethnic.

Detection

Newborn screening for X-ALD measures C26:0-lysophosphatidylcholine, C26:0-LPC, on the dried blood spot. The screen detects all three phenotypic forms because the biochemical abnormality is present from birth. New York added X-ALD to its panel in 2013 following advocacy by the parents of Aidan Seeger, a boy who died of cerebral X-ALD whose family successfully pushed for state-level screening (Aidan's Law). X-ALD was added to the federal Recommended Uniform Screening Panel in 2016. Most US states now screen.

Confirmation includes plasma VLCFA measurement and ABCD1 sequencing. The screening identifies affected boys, but it cannot predict at birth which boys will develop the cerebral form versus AMN-only. Surveillance for the development of cerebral lesions is the central post-screening management problem.

What management looks like

For boys identified by newborn screening, the central surveillance question is whether and when cerebral demyelination will develop. Brain MRI surveillance, typically annually from age 2 or 3 through adolescence, looks for the early signs of cerebral involvement. The Loes score, a standardized MRI scoring system, quantifies the extent of demyelination and informs treatment timing. Adrenal function surveillance with periodic ACTH stimulation testing identifies adrenal insufficiency before crisis.

For the cerebral form, allogeneic hematopoietic stem cell transplantation has been the standard intervention since the late 1990s. Transplantation performed at an early stage of cerebral demyelination, typically Loes score below 9 with limited neurological involvement, can stabilize the disease and preserve substantial neurological function. Transplantation at advanced stages or after significant neurological decline rarely halts progression and often precipitates further deterioration.

Skysona (elivaldogene autotemcel) provides an autologous alternative for boys with early cerebral X-ALD. The therapy uses the patient's own CD34-positive cells transduced ex vivo with a lentiviral vector encoding functional ABCD1, then reinfused after myeloablative conditioning. Published clinical trial data show neurological stabilization at rates similar to allogeneic HSCT in pre-progression early cerebral disease, with the advantage of avoiding allogeneic graft-versus-host disease. The list price at launch was approximately $3 million. The therapy carries a risk of insertional oncogenesis from the lentiviral vector, with documented cases of myelodysplastic syndrome reported in trial follow-up, which contributed to a label that prioritizes use after consideration of allogeneic transplant in eligible candidates.

Adrenal insufficiency is treated with standard glucocorticoid replacement, with stress dosing protocols and a medical alert identifier. Adrenomyeloneuropathy is managed with symptom-directed care, physical therapy, and surveillance.

Lorenzo's oil, the four-to-one mixture of glyceryl trioleate and glyceryl trierucate, lowers plasma VLCFA levels in many recipients but has not demonstrated meaningful clinical benefit for cerebral X-ALD in randomized study, and does not treat adrenal insufficiency. Its role in modern X-ALD management is limited.

What this looks like for a family

A baby boy is born and the heel-prick is sent. On day 5, the state lab reports an elevated C26:0-LPC. On day 7, ABCD1 sequencing confirms a pathogenic variant. The family meets the metabolic neurologist, the endocrinologist, and the genetic counselor. The MRI surveillance schedule is set. The adrenal surveillance schedule is set. Years pass. The MRIs remain stable.

At age 7, a routine surveillance MRI shows a small enhancing lesion in the splenium of the corpus callosum. Loes score is 2. The family is referred to a transplant center experienced in X-ALD. The decision is between allogeneic HSCT, if a donor is identified, and Skysona. The transplant happens. Surveillance continues. Adrenal insufficiency is identified at age 12 on an ACTH stimulation test and hydrocortisone replacement begins.

Without screening, the boy in this story would have presented to a pediatrician somewhere between his fourth and tenth birthdays with behavioral or cognitive regression. The MRI would show advanced demyelination. The transplant window would have closed. The disease would have run its historical course.

The screen rewrote the timeline. The treatments that the timeline allowed exist because of decades of work by clinicians, scientists, and families that the cultural memory of one film does not capture.